NEW YORK, April 27, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Wells Fargo & Company (NYSE: WFC), Mylan N.V. (NASDAQ: MYL), Great Basin Scientific, Inc. (NASDAQ: GBSN), Pfizer, Inc. (NYSE: PFE), and AbbVie Inc. (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
WFC Research Report: ( http://get.analystsreview.com/pdf/?c=Wells%20Fargo&d=27-Apr-2015&s=WFC ),
MYL Research Report: ( http://get.analystsreview.com/pdf/?c=Mylan&d=27-Apr-2015&s=MYL ),
GBSN Research Report: ( http://get.analystsreview.com/pdf/?c=Great%20Basin&d=27-Apr-2015&s=GBSN ),
PFE Research Report: ( http://get.analystsreview.com/pdf/?c=Pfizer&d=27-Apr-2015&s=PFE ),
ABBV Research Report: ( http://get.analystsreview.com/pdf/?c=AbbVie&d=27-Apr-2015&s=ABBV ).
Analyst Update: Results of Programs, Product Launches, FDA Clearance, Dividends, and Quarterly Results
Reviewed by: Rohit Tuli, CFA®
U.S. stocks advanced higher on Friday, April 24, 2015, led by strong first quarter results of major technology heavyweights. The NASDAQ Composite advanced 0.71%, to close at 5,092.09; the Dow Jones Industrial Average rose 0.12%, to finish the day at 18,080.14, and the S&P 500 finished at 2,117.69, up 0.23%. European stocks recovered on Friday, following a disappointing run on previous trading session. Germany's DAX 30 rose 0.74%; France's CAC 40 advanced 0.44%, and London's FTSE 100 gained 0.24% on Friday. Meanwhile, major Asian stock markets fell on Friday as China's securities regulator announced to accelerate approval of initial public offerings in a seeming effort to cool the red hot market. The Shanghai Composite and Japan's Nikkei both closed lower on Friday.
The Wells Fargo Startup Accelerator program of Wells Fargo & Company (Wells Fargo) has selected three early-stage U.S. companies for its spring 2015 program, wherein the companies will learn to commercialize and market their ideas to enterprises.
On April 23, 2015, Mylan NV (Mylan) announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep™ in India. The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regiment.
Great Basin Scientific, Inc. (Great Basin) announced that its molecular diagnostic test for Group B Streptococcus (GBS) has received clearance from the U.S. Food and Drug Administration (FDA).
Great Basin plans to launch the GBS assay commercially in Q2 2015.
The Board of Directors of Pfizer, Inc. (Pfizer) at its Annual Meeting of Shareholders held on April 23, 2015, declared a Q2 2015 dividend of $0.28 on the Company's common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015.
AbbVie Inc.'s (AbbVie) revenue for Q1 2015 increased 10.5% YoY to $5.0 billion while adjusted EPS rose 32.4% YoY to $0.94, exceeding previous guidance range of $0.82 to $0.84. The Company also raised its outlook for full-year 2015.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review